Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.38 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.38 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.38 |
| ▸ | HTR3B | O95264 | 1/20 | 0.38 |
| ▸ | HTR3A | P46098 | 1/20 | 0.38 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.38 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.38 |
| ▸ | SYK | P43405 | 1/20 | 0.37 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.36 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.36 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.36 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.36 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 5/20 | 0.35 |
| ▸ | HDAC4 | P56524 | 4/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30011457 | 1.00 | EGFR (0.43) | EGFRMAPK10ROCK1HTR3EHTR3B | |
| SCHEMBL30010939 | 0.85 | ROCK1 (0.46) | MAPK10ROCK1HTR3EHTR3BHTR3A | |
| SCHEMBL20162211 | 0.85 | ROCK1 (0.46) | MAPK10ROCK1HTR3EHTR3BHTR3A | |
| SCHEMBL18387056 | 0.82 | AURKA (0.44) | MAPK10ROCK1HTR3EHTR3BHTR3A | |
| SCHEMBL18386919 | 0.82 | APP (0.40) | MAPK10ROCK1HTR3EHTR3BHTR3A | |
| SCHEMBL17683162 | 0.79 | ROCK1 (0.47) | EGFRROCK1PIK3CAPIK3CBPIK3CG | |
| SCHEMBL30459783 | 0.79 | ROCK1 (0.47) | EGFRROCK1PIK3CAPIK3CBPIK3CG | |
| SCHEMBL18387036 | 0.78 | MAPK10 (0.57) | EGFRMAPK10ROCK1HTR3EHTR3B | |
| SCHEMBL11971017 | 0.75 | SYK (0.39) | EGFRROCK1SYKPIK3CAPIK3CB | |
| SCHEMBL5263722 | 0.74 | PIK3CA (0.48) | ROCK1SYKPIK3CAPIK3CBPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3323817-B1 | ANILINE PYRIMIDINE DERIVATIVES AND USES THEREOF | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD (CN) | 2022-10-19 | — | — | EP | disclosed |
| US-10329277-B2 | N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((4-(3-methyl-2-OXO-2,3-dihydro-1h-benzo[d]imidazol-1-yl)pyrimidin-2-yl)amino)phenyl)acrylamide hydrochloride as an inhibitor of epidermal growth factor receptor activity | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2019-06-25 | — | — | US | disclosed |
| US-10329277-B2 | N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((4-(3-methyl-2-OXO-2,3-dihydro-1h-benzo[d]imidazol-1-yl)pyrimidin-2-yl)amino)phenyl)acrylamide hydrochloride as an inhibitor of epidermal growth factor receptor activity | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2019-06-25 | — | — | US | disclosed |
| US-20180208581-A1 | ANILINE PYRIMIDINE DERIVATIVES AND USES THEREOF | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2018-07-26 | — | — | US | disclosed |
| US-20180208581-A1 | ANILINE PYRIMIDINE DERIVATIVES AND USES THEREOF | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2018-07-26 | — | — | US | disclosed |
| US-20180208581-A1 | ANILINE PYRIMIDINE DERIVATIVES AND USES THEREOF | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2018-07-26 | — | — | US | disclosed |
| EP-3323817-A1 | ANILINE PYRIMIDINE DERIVATIVES AND USES THEREOF | Chia Tai Tianqing Pharmaceutical Group Co.,Ltd (CN) | 2018-05-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180208581-A1 | ANILINE PYRIMIDINE DERIVATIVES AND USES THEREOF | EGFR, ERBB2, ERBB3 | EGFR 1/4885MAPK10 451/4885ROCK1 2625/4885 |
| US-10329277-B2 | N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((4-(3-methyl-2-OXO-2,3-dihydro-1h-benzo[d]imidazol-1-yl)pyrimidin-2-yl)amino)phenyl)acrylamide hydrochloride as an inhibitor of epidermal growth factor receptor activity | EGFR, ERBB2, ERBB3 | EGFR 1/4885MAPK10 456/4885ROCK1 3885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.